Cargando…
LOXL2—A New Target in Antifibrogenic Therapy?
The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resolut...
Autores principales: | Puente, Angela, Fortea, Jose Ignacio, Cabezas, Joaquin, Arias Loste, Maria Teresa, Iruzubieta, Paula, Llerena, Susana, Huelin, Patricia, Fábrega, Emilio, Crespo, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480111/ https://www.ncbi.nlm.nih.gov/pubmed/30986934 http://dx.doi.org/10.3390/ijms20071634 |
Ejemplares similares
-
Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy
por: Puente, Angela, et al.
Publicado: (2019) -
Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding
por: Fortea, José Ignacio, et al.
Publicado: (2018) -
Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It
por: Puente, Angela, et al.
Publicado: (2019) -
Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNγ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells
por: Arias-Loste, María Teresa, et al.
Publicado: (2021) -
Fatty Liver Disease, Metabolism and Alcohol Interplay: A Comprehensive Review
por: Odriozola, Aitor, et al.
Publicado: (2023)